CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Curis, Inc.
Curis, Inc.
BeOne Medicines
Lyell Immunopharma, Inc.
Innate Pharma
Bristol-Myers Squibb
Verismo Therapeutics
Incyte Corporation
Merck Sharp & Dohme LLC
Genmab
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Grifols Therapeutics LLC
Janssen Research & Development, LLC
Genmab
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Janssen Research & Development, LLC
TCRx Therapeutics Co.Ltd
Janssen Research & Development, LLC
Conjupro Biotherapeutics, Inc.
Adicet Therapeutics
Merck Sharp & Dohme LLC
Novartis
Regeneron Pharmaceuticals
Arovella Therapeutics Ltd
Hoffmann-La Roche
Hoffmann-La Roche
Actuate Therapeutics Inc.
Artiva Biotherapeutics, Inc.
AstraZeneca
Novartis
Eli Lilly and Company
Pfizer
Acerta Pharma BV
Hoffmann-La Roche
Prescient Therapeutics, Ltd.
Eli Lilly and Company
iOnctura
Vironexis Biotherapeutics Inc.
VIVUS LLC
Treeline Biosciences, Inc.
C4 Therapeutics, Inc.
AbbVie
Eli Lilly and Company
Hoffmann-La Roche
Cellectar Biosciences, Inc.
Cellectar Biosciences, Inc.
Pharmacyclics LLC.
Novartis
Galapagos NV